Clinical relevance of mechanisms of antifungal drug resistance in yeasts

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 20, Issue 9, 2002, Pages

  Sanglard, Dominique ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Antifungal drug resistance; Candida; Cryptococcus

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; LANOSTEROL; MICAFUNGIN; POSACONAZOLE; RAVUCONAZOLE; VORICONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIFUNGAL ACTIVITY; CANDIDA; CANDIDIASIS; CRYPTOCOCCOSIS; DRUG MECHANISM; DRUG TARGETING; DRUG TRANSPORT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYCOSIS; NONHUMAN; REVIEW;

EID: 0036858135     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0213-005x(02)72842-5     Document Type: Review

References (44)

1. Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA, et al. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 1997;24:235-47.
2. Rex JH, Cooper CR, Jr., Merz WG, Galgiani JN, Anaissie EJ. Detection of amphotericin B-resistant Candida isolates in a broth-based system. Antimicrob Agents Chemother 1995;39:906-9.
3. Peyron F, Favel A, Michel-Nguyen A, Gilly M, Regli P, Bolmstrom A. Improved detection of amphotericin B-resistant isolates of Candida lusitaniae by Etest. J Clin Microbiol 2001;39:339-42.
4. Pfaller MA, Messer SA, Hollis RJ. Strain delineation an antifungal susceptibilities of epidemiologically releated and unrelated isolates of Candida lusitaniae. Diagnostic Microbiology and Infectious Disease. 1994;20:127-33.
5. Walsh TJ, Melcher GP, Rinaldi MG, Lecciones J, McGough DA, Kelly P, et al. Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. Journal of Clinical Microbiology 1990;28:1616-22.
6. Nolte FS, Parkinson T, Falconer DJ, Dix S, Williams J, Gilmore C, et al. Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrobial Agents and Chemotherapy 1997;44:196-9.
7. Kelly SL, Lamb DC, Taylor M, Corran AJ, Baldwin BC, Powderly WG. Resistance to amphotericin B associated with defective sterol delta 8-7 isomerase in a Cryptococcus neoformans strain from an AIDS patient. FEMS Microbiol Lett 1994;122:39-42.
8. Dick JD, Merz WG, Saral R. Incidence of polyene-resistant yeasts recovered from clinical specimens. Antimicrob Agents Chemother 1980;18:158-63.
9. Sokol-Anderson ML, Brajtburg J, Medoff G. Amphotericin B-induced oxidative damage and killing of Candida albicans. Journal of Infectious Diseases 1986;154:76-83.
10. Polak A. Mode of action studies. In: Ryley JF, editor. Chemotheray of Fungal Diseases. Berlin: Springer-Verlag, 1990; p. 153-82.
11. Coleman DC, Rinaldi MG, Haynes KA, Rex JH, Summerbell RC, Anaissie EJ, et al. Importance of Candida species other than Candida albicans as opportunistic pathogens. Med Mycol 1998;36:156-65.
12. Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents: A comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol 1998;44:343-500.
13. Rex JH, Bennett JE, Sugar AM, Pappas PG, Van der Horst CM, Edwards JE, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994;331:1325-30.
14. White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998;11:382-402.
15. Sanglard D, Bille J. Current Understanding of the Mode of Action and of Resistance Mechanisms to Conventional and Emerging Antifungal Agents for Treatment of Candida Infections. Candida and Candidiasis. R. Calderone. Washington: ASM Press, 2002; p. 349-83.
16. Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod M, Bille J. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrobial Agents and Chemotherapy 1995;39:2378-86.
17. Sanglard D, Ischer F, Monod M, Bille J. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: Characterization of CDR2, a new multidrug ABC-transporter gene. Microbiology 1997;143:405-16.
18. Mart KA, Lyons CN, Rustad TR, Bowden RA, White TC, Rustad T. Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR. Antimicrob Agents Chemother 1998;42:2584-9.
19. Marr KA, Lyons CN, Ha K, Rustad TR, White TC. Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans. Antimicrob Agents Chemother 2001;45:52-9.
20. Sanglard D, Ischer F, Bille J. Role of ATP-binding-cassette transporter genes in high-frequency acquisition of resistance to azole antifungals in Candida glabrata. Antimicrob Agents Chemother 2001;45:1174-83.
21. Sanglard D, Ischer F, Monod M, Bille J. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob Agents Chemother 1996;40:2300-5.
22. Vanden Bossche H, Marichal P, Gorrens J, Bellens D, Moereels H, Janssen PAJ. Mutation in cytochrome P450-dependent 14a-demethylase results in decreased affinity for azole antifungals. Biochemical Society Transactions 1990;18:56-9.
23. Lamb DC, Corran A, Baldwin BC, Kwon-Chung J, Kelly SL. Resistant P450A1 activity in azole antifungal tolerant Cryptococcus neoformans from AIDS patients. FEBS Letters 1995;368:326-30.
24. Sanglard D, Ischer F, Koymans L, Bille J. Amino acid substitutions in the cytochrome P450 lanosterol 14a-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contributing to the resistance to azole antifungal agents. Antimicrob Agents Chemother 1998;42:241-53.
25. Marichal P, Vanden Bossche H, Odds FC, Nobels G, Warnock DW, Timmerman V, et al. Molecular biological characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother 1997;41:2229-37.
26. De Backer MD, Ilyina T, Ma XJ, Vandoninck S, Luyten WH, Vanden Bossche H. Genomic profiling of the response of Candida albicans to itraconazole treatment using a DNA microarray. Antimicrob Agents Chemother 2001;45:1660-70.
27. Miyazaki Y, Geber A, Miyazaki H, Falconer D, Parkinson T, Hitchcock C, et al. Cloning, sequencing, expression and allelic sequence diversity of ERG3 (C-5 sterol desaturase gene) in Candida albicans. Gene 1999;236:43-51.
28. Perea S, Lopez-Ribot JL, Kirkpatrick WR, McAtee RK, Santillan RA, Martinez M, et al. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2001;45:2676-84.
29. Sanglard D, Ischer F, Calabrese D, Majcherczyk PA, Bille J. The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents. Antimicrob Agents Chemother 1999;43:2753-65.
30. Ramage G, Bachmann S, Patterson TF, Wickes BL, Lopez-Ribot JL. Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J Antimicrob Chemother 2002;49:973-80.
31. Martins MD, Lozano-Chiu M, Rex JH. Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients. Clin Infect Dis 1998;27:1291-4.
32. Sobel JD, Ohmit SE, Schuman P, Klein RS, Mayer K, Duerr A, et al. The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis 2000;183:286-93.
33. Sanglard D, Odds FC. Resistance of Candida species to antifungal agents: Molecular mechanisms and clinical consequences. Lancet Infect Dis 2002;2:73-85.
34. Brandt ME, Pfaller MA, Hajjeh RA, Hamill RJ, Pappas PG, Reingold AL, et al. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998. Antimicrob Agents Chemother 2001;45:3065-9.
35. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Doern GV, Brandt ME, et al. Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. Diagn Microbiol Infect Dis 1999;33:217-22.
36. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Doern GV, Brandt ME, et al. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, SCH 56592, and voriconazole. Antimicrob Agents Chemother 1998;42:3242-4.
37. Yildiran ST, Saracli MA, Fothergill AW, Rinaldi MG. In vitro susceptibility of environmental Cryptococcus neoformans variety neoformans isolates from Turkey to six antifungal agents, including SCH56592 and voriconazole. Eur J Clin Microbiol Infect Dis 2000;19:317-9.
38. Yamazumi T, Pfaller MA, Messer SA, Houston A, Hollis RJ, Jones RN. In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans. Antimicrob Agents Chemother 2000;44:2883-6.
39. Bartizal K, Gill CJ, Abruzzo GK, Flattery AM, Kong L, Scott PM, et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother 1997;41:2326-32.
40. Mikamo H, Sato Y, Tamaya T. In vitro antifungal activity of FK463, a new water-soluble echinocandin like lipopeptide. J Antimicrob Chemother 2000;46:485-7.
41. Chavez M, Bernal S, Valverde A, Gutierrez MJ, Quindos G, Mazuelos EM. In vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients. J Antimicrob Chemother 1999;44:697-700.
42. Pfaller MA, Messer SA, Coffman S. In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents. Antimicrob Agents Chemother 1997;41:763-6.
43. Tawara S, Ikeda F, Maki K, Morishita Y, Otomo K, Teratani N, et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000;44:57-62.
44. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998;36:2950-6.